Ibogaminalog
Chemical compound
From Wikipedia, the free encyclopedia
Ibogaminalog (developmental code name DM-506) is a non-selective and non-psychedelic serotonin receptor modulator of the ibogalog group related to the iboga alkaloid ibogamine but with a simplified chemical structure. It was first described in the 1960s but was subsequently further studied and reported on in the 2020s.[1][2][3][4][5][6]
| |
 | |
| Clinical data | |
|---|---|
| Other names | DM-506; DM506 |
| Drug class | Non-selective serotonin receptor modulator; Non-hallucinogenic serotonin 5-HT2A receptor partial agonist |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C13H16N2 |
| Molar mass | 200.285 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pharmacology
Ibogaminalog is known to act as an agonist of serotonin receptors, including of the serotonin 5-HT2A receptor (Ki = 17–11,190 nM; EC50 = 2.9–34 nM; Emax = 33–76%), the serotonin 5-HT2B receptor (Ki = 16.5–63,780 nM; EC50 = 2.9–33 nM; Emax = 68–69%), and the serotonin 5-HT6 receptor (EC50 = 2.9 nM; Emax = 96%), and as an inverse agonist of the serotonin 5-HT7 receptor (Imax = 14%).[4][3][7][8]
It is a weak to very weak monoamine reuptake inhibitor, including of serotonin, norepinephrine, and dopamine (IC50 = 3,100 nM, 9,500 nM, and 70,000 nM, respectively), whereas it is not a significant monoamine oxidase inhibitor (MAOI) of MAO-A or MAO-B.[7] The drug also acts weakly as a negative allosteric modulator of the α7 and α9α10 nicotinic acetylcholine receptors.[2]
Ibogaminalog does not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and hence may be non-hallucinogenic in humans.[4] On the other hand, it has been found to produce sedative, antidepressant-like, anxiolytic-like, antiaddictive-like, and analgesic-like effects in rodents.[4][7][5][3]